What is the appropriate management for a 56-year-old patient with total cholesterol 223 mg/dL, HDL cholesterol 68 mg/dL, triglycerides 76 mg/dL, and LDL cholesterol 138 mg/dL?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management Recommendation

For this 56-year-old patient with LDL-C 138 mg/dL, you must first calculate their 10-year ASCVD risk using the Pooled Cohort Equations to determine whether statin therapy is indicated 1.

Risk Assessment Framework

The 2018 AHA/ACC guidelines prioritize risk-based treatment decisions for primary prevention 2, 1. Your immediate next steps are:

1. Calculate 10-Year ASCVD Risk

Use the Pooled Cohort Equations incorporating:

  • Age (56 years)
  • Sex
  • Race/ethnicity
  • Total cholesterol (223 mg/dL)
  • HDL-C (68 mg/dL)
  • Systolic blood pressure
  • Treatment for hypertension (if applicable)
  • Diabetes status
  • Current smoking status

2. Treatment Thresholds Based on Risk

If 10-year ASCVD risk ≥7.5%:

  • Initiate moderate-intensity statin therapy (reduces LDL-C by 30-50%) 1
  • Target: ≥30% LDL-C reduction
  • If risk ≥20%, consider high-intensity statin for ≥50% LDL-C reduction

If 10-year ASCVD risk 5-7.5% (borderline):

  • Engage in clinician-patient risk discussion 1
  • Assess for risk-enhancing factors that favor statin initiation:
    • Family history of premature ASCVD
    • Metabolic syndrome
    • Chronic kidney disease
    • Chronic inflammatory disorders (rheumatoid arthritis, psoriasis, HIV)
    • South Asian ancestry
    • Persistently elevated triglycerides ≥175 mg/dL
    • If measured: high-sensitivity CRP ≥2.0 mg/L, lipoprotein(a) ≥50 mg/dL, ankle-brachial index <0.9

If 10-year ASCVD risk <5%:

  • Lifestyle modifications are primary intervention 1
  • Statin therapy generally not indicated unless severe risk factors present

3. Consider Coronary Artery Calcium (CAC) Scoring if Uncertain

When the decision about statin therapy remains unclear after risk calculation (particularly in the 7.5-19.9% risk range), CAC scoring provides additional specificity 1:

  • CAC = 0: May defer statin therapy with focus on lifestyle modifications; reassess in 5 years (exception: smokers, diabetics, strong family history)
  • CAC 1-99: Favors statin therapy, especially if age ≥55 years
  • CAC ≥100 or ≥75th percentile: Statin therapy indicated

Baseline Lipid Profile Analysis

Your patient's current values:

  • Total cholesterol 223 mg/dL: Borderline high
  • HDL-C 68 mg/dL: Excellent (protective level >60 mg/dL)
  • Triglycerides 76 mg/dL: Optimal (<150 mg/dL)
  • LDL-C 138 mg/dL: Borderline high for primary prevention
  • Non-HDL-C: 155 mg/dL (calculated as 223-68)

The favorable HDL-C and triglyceride levels are positive, but the elevated LDL-C warrants intervention based on overall ASCVD risk 1.

Foundational Lifestyle Interventions

Regardless of statin decision, initiate therapeutic lifestyle changes immediately 2, 1:

  • Dietary modifications:

    • Saturated fat <7% of total calories
    • Dietary cholesterol <200 mg/day
    • Eliminate trans fats
    • Increase plant stanols/sterols (2 g/day)
    • Increase viscous fiber (10-25 g/day)
    • Emphasize Mediterranean or DASH dietary patterns

  • Physical activity: ≥150 minutes/week moderate-intensity or 75 minutes/week vigorous-intensity aerobic activity

  • Weight management: If BMI ≥25 kg/m², target 5-10% weight reduction

  • Smoking cessation: If applicable (major risk enhancer)

Statin Therapy Specifics

Moderate-intensity statins (30-50% LDL-C reduction) 1:

  • Atorvastatin 10-20 mg
  • Rosuvastatin 5-10 mg
  • Simvastatin 20-40 mg
  • Pravastatin 40-80 mg
  • Lovastatin 40 mg
  • Fluvastatin 80 mg

High-intensity statins (≥50% LDL-C reduction) 1:

  • Atorvastatin 40-80 mg
  • Rosuvastatin 20-40 mg

Critical Shared Decision-Making Elements

Before initiating statin therapy, conduct a clinician-patient risk discussion covering 1:

  • Absolute 10-year ASCVD risk percentage
  • Presence of risk-enhancing factors
  • Potential benefits: relative risk reduction of 25-30% for major cardiovascular events per 40 mg/dL LDL-C reduction
  • Potential adverse effects: statin-associated muscle symptoms (5-10%), new-onset diabetes (0.1-0.2% per year), drug-drug interactions
  • Patient preferences and values
  • Cost considerations

Follow-Up Monitoring

Reassess lipid panel 4-12 weeks after statin initiation to evaluate 1:

  • Adherence to therapy
  • Percentage LDL-C reduction achieved
  • Need for dose adjustment

Do not add non-statin therapy (ezetimibe, PCSK9 inhibitors) in primary prevention unless LDL-C remains ≥190 mg/dL despite maximally tolerated statin therapy 1.

Key Clinical Pitfalls to Avoid

  1. Do not use LDL-C thresholds alone without calculating 10-year ASCVD risk in primary prevention—this is the most common error 1

  2. Do not ignore risk-enhancing factors when risk is borderline (5-7.5%)—these tip the balance toward treatment 1

  3. Do not treat to specific LDL-C targets in primary prevention; the 2018 guidelines emphasize percentage reduction and risk-based thresholds rather than treat-to-target approaches used in European guidelines 3, 1

  4. Do not measure lipids in a fasting state unless triglycerides are suspected to be >400 mg/dL—non-fasting measurements are acceptable and more convenient 1

  5. Do not overlook the excellent HDL-C level (68 mg/dL)—this provides significant cardiovascular protection and should be factored into the overall risk discussion

The evidence strongly supports that the single most important determinant of whether this patient needs statin therapy is their calculated 10-year ASCVD risk, not the isolated LDL-C value of 138 mg/dL 2, 1.

References

Related Questions

How should a patient with hypercholesterolemia and a lipid panel showing total cholesterol 280 mg/dL, LDL (low-density lipoprotein) 143 mg/dL, HDL (high-density lipoprotein) 117 mg/dL, and triglycerides 100 mg/dL be managed?
What is the diagnosis and recommended treatment for a 44-year-old man with total cholesterol 227 mg/dL, HDL cholesterol 45 mg/dL, triglycerides 182 mg/dL, LDL cholesterol 150 mg/dL, non‑HDL cholesterol 182 mg/dL, and cholesterol/HDL ratio 5.0?
What is the appropriate management for a 40-year-old man with total cholesterol 237 mg/dL, high-density lipoprotein cholesterol 75 mg/dL, low-density lipoprotein cholesterol 145 mg/dL, apolipoprotein B 96 mg/dL, no diabetes, no hypertension, not taking statins, non‑smoker, and no other cardiovascular risk factors?
In a 68-year-old woman with total cholesterol 198 mg/dL, triglycerides 65 mg/dL, HDL‑C 86 mg/dL, LDL‑C 102 mg/dL, and non‑HDL‑C 112 mg/dL, what is the recommended management?
What lipid‑lowering treatment should be initiated for a 71‑year‑old female with total cholesterol 244 mg/dL, LDL‑cholesterol 134 mg/dL, HDL‑cholesterol 96 mg/dL, triglycerides 68 mg/dL, and non‑HDL‑cholesterol 148 mg/dL?
How can I replace the combination tablet Condo XR 5‑1000 (dapagliflozin/metformin) with separate dapagliflozin and metformin therapy?
For how many days should a patient take naproxen 500 mg twice daily for foot pain?
Is the Respiratory Event Index (REI) the same as the Apnea‑Hypopnea Index (AHI)?
Which antipsychotic medication is associated with the fewest withdrawal symptoms in an adult without contraindications?
What are the clinical signs of anaphylaxis?
How should a 10½‑year‑old with iatrogenic thoracic duct injury from C5‑C6 anterior cervical discectomy and fusion presenting with acute chest pressure, dyspnea, facial and neck edema, pulsatile ear sounds, dysphagia, cough, cyanotic extremities, tachycardia, and new‑onset hypotension be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.